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Bioimpedance-defined 
overhydration predicts survival in 
end stage kidney failure (ESKF): 
systematic review and subgroup 
meta-analysis
Matthew Tabinor  , Emma Elphick, Michael Dudson, Chun Shing Kwok  , Mark Lambie & 
Simon J. Davies  
Both overhydration and comorbidity predict mortality in end-stage kidney failure (ESKF) but it is not 
clear whether these are independent of one another. We undertook a systematic review of studies 
reporting outcomes in adult dialysis patients in which comorbidity and overhydration, quantified 
by whole body bioimpedance (BI), were reported. PubMed, EMBASE, PsychInfo and the Cochrane 
trial database were searched (1990–2017). Independent reviewers appraised studies including 
methodological quality (assessed using QUIPS). Primary outcome was mortality, with secondary 
outcomes including hospitalisation and cardiovascular events. Of 4028 citations identified, 46 matched 
inclusion criteria (42 cohorts; 60790 patients; 8187 deaths; 95% haemodialysis/5% peritoneal dialysis). 
BI measures included phase angle/BI vector (41%), overhydration index (39%) and extra:intracellular 
water ratio (20%). 38 of 42 cohorts had multivariable survival analyses (MVSA) adjusting for age (92%), 
gender (66%), diabetes (63%), albumin (58%), inflammation (CRP/IL6–37%), non-BI nutritional markers 
(24%) and echocardiographic data (8%). BI-defined overhydration (BI-OH) independently predicted 
mortality in 32 observational cohorts. Meta-analysis revealed overhydration >15% (HR 2.28, 95% CI 
1.56–3.34, P < 0.001) and a 1-degree decrease in phase angle (HR 1.74, 95% CI 1.37–2.21, P < 0.001) 
predicted mortality. BI-OH predicts mortality in dialysis patients independent of the influence of 
comorbidity.
Observational studies have demonstrated an association between overhydration (OH) and mortality within dial-
ysis patients1,2. Fluid status is difficult to assess clinically, risking either hypovolaemia, intradialytic hypotension 
and loss of residual renal function, or persistent overhydration, manifesting as large interdialytic weight gains, 
hypertension, left ventricular hypertrophy, peripheral and pulmonary oedema3. As such, clinical methods includ-
ing examination for oedema, minimising interdialytic weight gain or removing fluid until the point of hypoten-
sion, known as “probing the dry weight”, are increasingly recognised as inadequate3. Gold standard methods 
in contrast, such as isotope dilution, are more precise, but have been found to be expensive, laborious and not 
appropriate for mass application in the clinical setting4. These limitations have led to the development of bio 
impedance as a non-invasive, bedside technique to aid the clinical assessment of fluid status and body compo-
sition5,6. Although based on the same principle, a number of approaches to bioimpedance analysis (BI) of body 
composition have been developed, including the estimation of bioimpedance vectors and their phase angle at sin-
gle (typically 50 MHz) or multiple frequencies (bio impedance spectroscopy3). Estimates of resistance, inversely 
proportional to measures of total body water, and reactance, proportional to intracellular mass, can then be used 
to model body composition7. These different approaches express OH in different ways, such as the phase angle 
(PA), extracellular fluid (ECF) volumes (normalised either to intracellular fluid, ECF/ICF, the total body water, 
ECF/TBW or height) or derivation of the overhydration index (OH/ECF), defined as the fluid excess or deficit 
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above or below the normally hydrated tissues, especially muscle3. Thus a patient may have a raised OH/ECF, i.e. 
above 15%, yet have a reduced muscle mass (thus TBW).
Overhydration in end-stage renal failure (ESRF) is both a function of salt and water excess and the conse-
quences of reduced muscle mass and abnormal body composition associated with comorbidity and inflammation. 
Such changes lead to both an absolute and relative expansion of the extracellular fluid volume (ECFv), causing 
progressive ECFv retention and clinical manifestations of overhydration3. The mechanisms underlying cachexia 
in dialysis patients include chronic inflammation, acidosis, anorexia, insulin resistance, anaemia and metabolic 
bone disease8. Substantial multimorbidity within ESRF patients precipitates physical weakness and decondition-
ing, further exacerbating muscle wasting8. Given that observational studies commonly measure hypoalbumi-
naemia, inflammation and the presence of comorbidities, which themselves predict mortality within the dialysis 
population, it is important to establish whether overhydration, as determined from body composition measure-
ments, is an independent predictor of survival.
The purpose of this review is to summarise the evidence regarding the use of whole-body BI in dialysis patients 
to explore whether BI-defined overhydration (BI-OH) is independently predictive of mortality. Where possible, 
quantitative pooling of outcome data was planned to determine the extent to which BI-OH can be treated as a 
mortality predictor. Secondary analyses were planned to explore whether BI-OH is predictive of morbidity related 
markers, such as re-hospitalisation. Studies invesitgating the role of whole-body BI-OH in heart failure (HF) were 
included to compare whether the relationship is consistent across different chronic disease groups.
Methods
Study design. The design and reporting of the systematic review protocol was guided by the Preferred 
Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)9. All studies reporting primary (mor-
tality) or secondary (re-hospitalisation/morbidity measures) outcome data, in adults with ESRF or HF, where 
whole-body BI measurements or degree of overhydration was specified, were considered appropriate for inclusion 
within the study.
Search Strategy and Selection Criteria. MEDLINE, EMBASE, PsychINFO and the Cochrane Register 
for Controlled Trials (CENTRAL) were searched from 01/01/1990 through to 06/11/2017 to identify relevant cita-
tions. 1990 was chosen as the lower cut off as BI machines were not routinely available prior to this date. Search 
terms included both medical subject headings (MeSH) and agreed a priori individual search terms. Reference lists 
from identified citations and selected manual journal searching was used to identify any further relevant studies 
that matched the inclusion criteria prior to data extraction. The search strategy used for CENTRAL is available as 
an appendix (see supplementary material).
Study Selection and Data Extraction. All retrieved citations were imported from the citation library 
into a central database (using Microsoft Excel 2011). Citations were assessed at the title and abstract level by two 
independent reviewers (MT and EE or SJD) using exclusion criteria: the study was in the paediatric population; 
the wrong BI measure was used (i.e. segmental and intrathoracic BI methods); the outcome of interest for our 
review was not reported (i.e. mortality and hospitalisation); there was no full paper available; or there was no 
English translation available. During abstract review, if the citation suggested that the study assessed prognostic 
outcome data, or if it was unclear from the abstract what the study outcomes were, then the citation was accepted 
for full paper review. Full paper review was conducted again using two independent reviewers (MT and MD or 
SJD), using the same exclusion criteria. Data extraction occurred both at the individual study level, using piloted 
study summaries (on Microsoft Word 2011), and in the form of review summary tables (on Excel 2011). No a 
priori assumptions were made regarding data quality.
Classification of BI method for expressing fluid status. Studies were sub-grouped according to 
whether they used phase angle (PA)/BI-vector analysis (BIVA), normalised ECF (ECF/TBW) or the overhydra-
tion index (OHI) as previously described3.
Risk of Bias (ROB) Assessment. Risk of bias (ROB) within studies was assessed by two independent 
reviewers (MT and MD or SJD) using the Quality in Prognostic Studies (QUIPS) tool10, which grades six separate 
study domains (selection of participants, study attrition, prognostic factor measurement, outcome measurement, 
study confounding and statistical analyses) according to their risk of Bias (low, medium or high risk of bias). If 
disagreements occurred then this was resolved following discussion between MT and MD.
Statistical Analyses and Meta Analysis Methods. All cohorts reporting multivariable survival analyses 
(MVSA) for outcome data (mortality odds ratio, risk ratio or hazard ratio with 95% confidence intervals) were 
considered for quantitative pooling in a meta-analysis. More than one cohort had to report the same BI-OH 
method and cut off value defining overhydration within MVSA to be included for pooling. In all PA cohorts 
mortality hazard ratios were expressed for every 1-degree increase in PA in initial MVSA. Therefore, to better 
reflect the effect of increasing overhydration defined by PA on mortality, individual cohort mortality HR and 95% 
confidence intervals were mathematically reciprocated before pooled summaries were produced. Random effects 
pooled summaries, using the generic inverse variance method, were produced using Review Manager 5.3 (Nordic 
Cochrane Centre). The I2 statistic was used to assess statistical heterogeneity, with I2 values between 30%–60% 
representing moderate levels of heterogeneity11.
Data availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request, including the full search strategy used to identify citations and the QUIPS paper 
summaries.
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Results
The search yielded 3054 citations following removal of duplicates and identification of 7 additional citations 
from selected manual journal searching and reference checking (Fig. 1). Detailed methodological review and 
data extraction process was conducted on 52 papers;1,2,12–61 46 from the ESKF population1,2,12,14–17,19,20,22–25,27–50,52–
59,61and 6 from the HF population13,18,21,26,51,60. Within ESKF studies 42 individual cohorts were identified, with 4 
cohorts having data reported in two separate studies.
Heterogeneity within the use of BI measurements of hydration status. The most common 
BI-OH measure, phase angle (PA) and the related measure of BI-vector analysis (BIVA), was reported in 41% 
of studies12–16,18,20–22,24–26,29,30,38,39,47,49,52–54,60. Overhydration indices (OHI), as a group, were reported in 39% of 
studies1,2,17,23,33–35,37,40–44,46,48,55–58,61. OHI was variably described, with relative fluid overload (RFO), overhydra-
tion normalised for extracellular water (OH/ECW), absolute overhydration in litres and the percentage hyper-
hydration compared to normally hydrated controls all being reported. Extracellular water ratios (ECWR) were 
reported in 20% of studies19,22,27,28,31,32,36,41,45,50,51,59, with ECW ratios being variably normalised for intracellular 
water (ECW/ICW), total body water (ECW/TBW) and body surface area (ECW/BSA). The changes in the use of 
different BI-OH measures over time are summarised in Fig. 2.
Patient demographics within ESKF and HF cohorts. 60,790 ESKF patients were identified in 42 sep-
arate cohorts (Table 1); cohort size ranged between 45 to 39,566 patients and within all cohorts 8,168 mortalities 
were reported. 57,563 patients were on haemodialysis (95%) and 3227 on peritoneal dialysis (5%). 20 (48%) 
cohorts were within Europe1,2,12,17,25,27,30,33,35,39,41,42,46,48,52,53,55–58, 5 (12%) within the USA, 9 (21%) within South East 
Asia, 2 (5%) within Central/South America, 3 (7%) within the Middle East15,16,24 and 1 (2%) within the Indian 
Subcontinent40. 2 cohorts (5%) were multinational studies23,61. Follow up ranged from 0–15 years (1 study stating 
a follow up of 339 years, which was thought to represent cumulative follow up25). Patient age, gender, ethnicity 
and diabetic status were reported in 100, 98, 29 and 90% of cohorts respectively. Mean age ranged between 38 
to 69 years1,2,12,14–17,19,20,22–25,27–50,52–59,61, the proportion of males between 31–79%1,12,14–17,19,20,22–25,27–50,52–59,61, the 
proportion of non-Caucasian patients between 2 to 100%14,20,28–30,38,41,42,46,47,49,58,61 and the proportion of patients 
who were diabetic between 8 to 58%1,12,14–17,19,20,22–25,27,29–36,38,40–48,50,52–59,61. HIV status was reported in 1 cohort28, 
Figure 1. PRISMA flow diagram. The flow diagram summarises the systematic search, citation screening, 
exclusion and inclusion processes undertaken within this review.
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and was cited as exclusion criteria in 6 others20,22,29,38,47,49. Primary renal disease (PRD) was described in 48% of 
cohorts12,16,22,25,29,30,37–39,41,43,44,46,49,50,56, with diabetic nephropathy (55%) and glomerulonephritis (30%) being the 
commonest aetiology respectively.
978 HF patients with were identified in 6 separate cohorts (Table 1); cohort size ranged between 41 to 389 
patients and within all cohorts 164 primary endpoints (129 mortalities/35 re-hospitalisations for heart failure) 
were identified. 2 (33%) cohorts were within Europe26,60, 1 (17%) within South East Asia51 and 3 (50%) within 
Central/South America13,18,21. Follow up ranged from 0–5 years. Patient age, gender, ethnicity and diabetic status 
were reported in 100, 100, 17 and 66% of cohorts respectively. Mean age ranged from 59 to 74 years13,18,21,26,51,60, 
the proportion of males from 39 to 88%13,18,21,26,51,60 and the proportion of patients with diabetes between 
37–59%18,21,51,60.
BI-defined overhydration, mortality and morbidity in ESKF. Within 42 ESRF cohorts, BI-OH was 
associated with an increased risk of mortality in 35 (83%). 39 cohorts were observational cohorts (Table 1). All 
3 observational cohorts with univariate analyses demonstrated that BI-OH is predictive of mortality in the PD 
population29,42,46. Within 36 observational cohorts containing a multivariable survival analysis (MVSA), 31 
demonstrated that BI-OH is an independent predictor of all cause1,2,12,14,15,17,19,20,23–25,27,28,30–32,35–41,44,45,47,50,52–56,58,61 
and cardiovascular mortality49, with a further cohort demonstrated BI-OH as an independent predictor of hos-
pitalisation16. 3 cohorts were randomised controlled trials (RCTs) assessing the role of BI versus standard care in 
determining fluid status in HD patients34,43,48. In the RCTs using a MVSA, 1 demonstrated using BI-OH provided 
independent survival benefit43 whereas 1 did not34. Details of covariates included in MVSA within each cohort 
are listed in supplementary Table 1. Looking at all cohorts, the adjusted covariates included demographics, such 
as age (92%1,2,12,14–17,19,20,22–24,27,28,30–32,34–39,41,43–45,47,49,50,52–59,61), ethnicity (16%14,20,28,41,47,61) and gender (66%1,2,12,14–
17,19,20,23,24,28,30–32,34,37,38,41,43–45,47,49,50,54,57); co-morbidities, such as diabetic status (63%1,2,14–17,20,23,24,27,28,30–33,36–38,41,43–
45,47,50,52,53,61), hypertension (32%1,2,22,24,31,32,35,36,38,44,45,59,61), cardiovascular disease (24%2,15,23,24,36,37,43,44,61), BMI 
(21%1,17,23,24,40,43,52,53,61), heart failure (11%23,35,52,53,61), HIV status (3%28) and co-morbidity scoring systems (21%12
,16,19,25,31,32,41,54,58); dialysis related factors such as dialysis vintage (50%1,2,12,15–17,20,23,24,28,30,38,41,43–45,47,52,53,55–57), dial-
ysis modality (5%22,45), Kt/V (29%2,16,19,20,24,31,32,37,38,47,49,50,61), peritoneal solute transport rate (3%31,32) and residual 
renal function (5%16,31,32); biochemical factors such as CRP (34%22,27,30–32,35,41,45,49,55–59,61), IL-6 (3%16), cholesterol 
(5%20,33), HbA/haematinics (18%1,20,24,25,37,47,57,61), albumin (58%1,2,17,19,20,24,25,27,30–33,35,37,38,41,45,47,49,50,55,56,58,59,61), 
phosphate (13%2,37,38,57,61) and BNP (11%2,45,57,61); non-BI nutritional markers (24%16,19,23,30,39,52,53,58,59,61); echo-
cardiographic markers such as left ventricular ejection fraction (3%44) and markers of left/interventricular wall 
thickness (8%33,44,55,56); symptomatic markers, such as NYHA classification of dyspnoea (5%55–57); and the dura-
tion of hospital admission (3%25).
In four observational studies using MVSA BI-OH did not independently predict adverse outcomes22,33,57,59. 
A Brazilian cohort demonstrated BI-OH was predictive of cardiovascular (CV) event rate in diabetics but not 
in non-diabetics22. This study, however, was relatively underpowered and reported cardiovascular event rate as 
opposed to mortality. A Polish cohort determined the effect of dialysis vintage on survival, with secondary anal-
yses exploring the effects of BI-OH, echocardiographic data and troponin levels on survival33. In this analysis, 
which included the cardiac biomarker troponin, BI-OH did independently predict mortality, but when adjusted 
for albumin, cholesterol and intraventricular septum thickness on echocardiography, this relationship was not 
seen. A Romanian cohort, which explored the additive value of BNP and relative overhydration (ROH) in pre-
dicting mortality in HD patients57 found that while these had an additive effect in predictiting survival, ROH 
alone was not an independent predictor, possibly due to relatively small numbers in this sub-group analysis. In 
a Chinese cohort of PD patients, increased extra-intra cellular water ratio was predictice of worse survival in 
MVSA, except of r the final models which incorporated C-reactive protein; again this was likely underpowered 
given the number of covariates used and low number of deaths59.
Figure 2. The temporal change in the reporting of BI-OH measures within studies according to year of 
publication. PA = phase angle, BIVA = Bioimpedance Vector Analysis, ECWR = Extracellular water expressed 
as a ratio (e.g. intracellular or total body water, OHI = overhydration index.
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End-Stage Kidney Failure Cohorts
Abad 2011 Spain HD+PD 164 6 yrs Mortality N/A 100 L M L L L M PA* PA < 8 (p < 0.01) and comorbidity (Charlson index) are independent predictors of mortality
Avram 2006 USA PD 177 15 yrs Mortality N/A 89 H H M M H H PA* PA (RR 0.54) and enrolment CRP were independent predictors of mortality.
Bebera-shvili 2014 Israel HD 91 3 yrs Mortality N/A 38 L L L L M L PA**
Patients with greatest decline of PA had highest 
risk for mortality. 1 degree increase in PA (when 
treated as time varying variable) has a mortality 
HR of 0.61 (95% CI 0.53–0.71)
Bebera-shvili 2014 Israel HD 250 1.4 yrs Mortality N/A 64 L L L L M M PA***
As a continuous variable PA has a mortality 
HR of 0.72 (95% CI 0.54–0.96). Adjustment for 
MIS Score nullified of PA as mortality predictor 
(HR 0.75, 95% CI 0.54–1.03) but remained a 
predictor of hospitalisation risk (HR 0,76, 95% 
CI 0.63–0.92)
Caetano 2016 Portugal HD 697 1 yr Mortality N/A 66 M L L M L M OHI**
OH/ECW >15% is an independent predictor 
of 1-year mortality during follow up (HR for 
mortality 2.22, 95% CI 1.29–3.79).
Chazot 2012 France HD 158 6.5 yrs Mortality Hypertension Unclear M L L L H M OHI**
Giessen cohort patients with hyperdration (OH/
ECW >15%) had worse cumulative survival 
than non-hyperhydrated patients (mortality HR 
3.41, 95% CI 1.62–7.17).
Chen 2007 China PD 227 3 yrs Mortality N/A 58 L L M L L M ECWR**
ECW/ICW is independent predicator of 
mortality in incident PD patients. Every 0.1 
increase in ECW/ICW (time dependent) 
associated with mortality RR 1.37 (95% CI 
1.10–1.70)
de Araujo 2013 Brazil HD+PD 145 1.3 yrs CV Events Mortality 13 M L M L L L PA
PA is predictive of CV events in non-diabetics 
(HR 0.56, 95% CI 0.38–0.83) but not in 
diabetics (HR 1.01, 95% CI 0.60–1.70). Study 
has small number of endpoints.
Dekker 2017 Inter-national HD 8883 1 yr Mortality N/A Unclear L L M M M H OHI**
Baseline pre-dialysis OHI/ECW >15% 
(overhydration 2.5–5L) is predictive of mortality 
(HR 2.62, 2.1–3.3), independent of comorbidity. 
Inflammation and FO in a dynamic cohort have 
additive effects on mortality in HD patients.
Demirci 2016 Turkey HD 493 2.3 yrs Mortality CV Mortality 93 L L L L M M BIVA**
When adjusted for comorbidities, impedance 
ratio is independently predictive for all cause 
mortality (HR 1.13, 95% CI 1.04–1.23) and 
cardiovascular mortality (HR 1.15, 95% CI 
1.03–1.27)
Di Iorio 2004 Italy HD 515 339 yrs^ Mortality N/A 75 L M M M L M PA* PA was an independent predictor of mortality in a HD population (RR 2.50).
Fan 2015 UK PD 183 1.7 yrs Mortality Technique Failure 37 L M M L M L ECWR**
In PD patients, ECW is an independent 
predictor of mortality, including in cases 
adjusted for peritonitis episodes (HR 2.98, 95% 
CI 1.40–7.30). Log CRP also an independent 
predictor of mortality (HR 3.32, 95% CI 
1.50–7.70).
Fein 2002 USA PD 45 0.6 yrs Mortality N/A 4 L M M M H H PA****
Univariate analysis revealed patients with 
PA < 6 had worse cumulative survival than 
those >6 (p < 0.01). No MVA present.
Fein 2008 USA PD 53 8 yrs Mortality N/A 21 H H L M M M ECWR*
Enrolement BIA measures (Avram et al., ECM/
BCM, RR 1.04/Fein et al., ECW/BSA, RR 1.50) 
were independent predictors of mortality. 
Avram et al. data included as same cohort*
Fiedler 2009 Germany HD 90 3 yrs Mortality
Hospital 
admission 
events
36 M L M L M L PA**
PA < 4 independently predicts mortality in HD 
patients (RR 2.34, 95% CI 1.06–5.14). Individual 
nutrition scores are superior to BIA in terms of 
prognostic utility.
Guo/Guo 2015 China PD 307 3.2 yrs Mortality CV Mortality 52 L L L L M L ECWR**
In CAPD patients ECW/TBW >0.40 is an 
independent predictor of all cause mortality 
(HR 13.12, 95% CI 1.35–128.00) and 
PD technique failure (HR 10.34, 95% CI 
1.88–57.02).
Hoppe 2015 Poland HD 241 2.5 yrs Mortality N/A 42 M H H M H H OHI
Troponin and OH index predict mortality in 1 
MVA, but when adjusted for other covariates, 
OH Index (continous variable) no longer an 
independent predictor of mortality (RR 1.12, 
95% CI 0.92–1.37).
Huan-Sheng 2016 Taiwan HD 298 1 yr
Hospital 
admission 
events
CV Events 13 QUIPS not validated for assessing bias in RCT OHI
No differences noted in all cause hospitalisation 
(HR 1.19, 95% CI 0.79–1.80), all cause mortality 
(HR 0.85, 95% CI 0.29–2.53) and fluid overload/
cardiovascular event rate (HR 0,57, 95% CI 
0.08–1.07) between the BIA and control groups.
Jotterand-
Drepper 2016 Germany PD 54 6.5 yrs Mortality N/A 19 L L M L M H OHI**
OHI/ECW >15% independently predictive 
of mortality (HR 7.82, 95% CI 1.10–29.07) 
in PD patients when adjusted for troponin 
values, CRP, the presence of heart failure and 
hypoalbuminaemia.
Continued
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Kim 2015 South Korea HD 240 2 yrs Mortality
Hospital 
admission 
events
50 M M L L M M OHI**
When adjusted for comorbidities, OH/ECW 
>15% was an independent predictor of 
mortality (HR 2.58, 95% CI 1.16–5.75). Age was 
also an independent predictor.
Kim 2017 South Korea HD 77 5 yrs Mortality CV Events 24 L L H L M M ECWR**
ECW/ICW ratio is an independent predictor 
of mortality (HR 1.12, 95% CI 1.01–1.25) 
and cardiovascular events (HR 1.09, 95% CI 
1.01–1.18) when adjusted for multiple co-
morbidities.
Koh 2011 Malaysia PD 128 2.2–2.3 yrs Mortality N/A 35 L M L L L M PA**
PA is a independent predictor of mortality in 
HD patients (HR 0.39, 95% CI 0.27–0.57).
Maggiore 1996 Italy HD 131 2.2 yrs Mortality N/A 23 M L L L H M PA*
When adjusting for age and other nutritional 
markers, PA is an independent predictor of 
mortality in HD patients (p < 0.01).
Mathew 2015 India HD+PD 99 2 yrs Mortality N/A 33 M L L L M L OHI**
Absolute overhydration (>3.1L) is an 
independent predictor of mortality (adjusted 
OR 2.96, 95% CI 1.04–8.46).
O’Lone 2014 UK PD 529 4 yrs Mortality N/A 95 M M L L H L OHI+ ECWR**
Where OH/ECW and ECW/TBW values are 
in the top 30% for the cohort, both OH/ECW 
(HR 2.09, 95% CI 1.36–3.20) and ECW/TBW 
(HR 2.05, 95% CI 1.31–3.22) act as independent 
predictors of mortality.
Oei 2016 UK PD 336 2 yrs Mortality N/A 48 L L M L H M OHI****
Univariate analysis correlates overhydration 
with cardiac death (p < 0.05), but no further 
analysis noted.
Onofriescu 2014 Romania HD 131 3.5 yrs Mortality Adverse Events 9
QUIPS not validated for assessing 
bias in RCT OHI**
RCT of BIA vs standard clinical care in 
determining ultrafiltration on HD. BIA group 
had survival advantage over standard clinical 
care group (HR 0.11, 95% CI 0.01–0.92). Study 
at risk of selection bias.
Onofriescu 2015 Romania HD 221 5.5 yrs Mortality CV Mortality 66 L L M L L L OHI**
OH/ECW >17.4%, when adjusted for 
comorbidities, is independently predictive for 
mortality when LVEF (HR 2.29, 95% CI 1.08–
4.89) and LVMI (HR 2.19, 95% CI 1.02–4.69) 
are adjusted for in the analysis.
Paniagua 2010 Mexico HD+PD 753 1.4 yrs Mortality CV Mortality 182 M L M L M L ECWR**
ECW/TBW (OR 1171.33, 95% CI 3.35–
409899.37) and NT-proBNP (OR 1.01, 95% 
CI 1.00–1.02) independently predictive of CV 
mortality but not all cause mortality (OR 84.64, 
95% CI 0.52–13788.55) in dialysis patients.
Paudel 2015 UK PD 455 2 yrs Mortality N/A 72 L H M M L H OHI****
Univariate analysis revealed OH index 
predictive of mortality. Multivariable model 
used to assess SGA independent of OH.
Pillon/
Chertow 2004 USA HD 3009
0–
1.5 yrs Mortality N/A 361 M L L M M M BIVA**
BIVA vector, per 100Ohm/m incremental 
increase, is independently predictive of 
mortality (RR 0.75, 95% 0.57–0.88).
Ponce 2014 Portugal HD 189 1 yr Mortality Adverse Events 20
QUIPS not validated for assessing 
bias in RCT OHI
Univariate analysis revealed survival (p = 0.33) 
and event-free-survival (p = 0.17) equivalent 
between BIA and control groups. The study was 
terminated prematurely.
Pupim 2004 USA HD 194 3 yrs Mortality CV Mortality 50 M M L L M L PA*
PA and Albumin independent predictors of 
cardiovascular mortality in MVA, although 
summary statistics from MVA not reported.
Rhee 2015 South Korea PD 129 2.1 yrs Residual RF Mortality 15 M H L M M H ECWR**
In Korean PD patients with preserved RRF, 
ECW/TBW is predictive of mortality (HR 
1.001, 95% CI 1.001–1.086) and, additionally, 
technique failure (HR 1.024, 95% CI 
1.001–1.048).
Segall/Segall 2014 Romania HD 149 1.1 yrs Mortality N/A 43 L M M M L L PA**
PA < 5.58 is independently predictor of 
mortality in HD patients (HR 2.15, 95% CI 
1.16–3.99).
Shin 2017 South Korea HD 142 2.4 yrs Mortality CV Mortality 15 L M M M H M PA**
PA is an independent predictor of all cause 
mortality (HR 0.56, 95% CI 0.33–0.97) and 
infection (HR 0.65, 95% CI 0.45–0.94) in HD 
patients, but not for cardiovascular mortality 
(HR 0.92, 95% CI 0.43–2.14).
Siriopol/
Siriopol 2015 Romania HD 173 1.8 yrs Mortality N/A 31 L M M L H H OHI**
OH/ECW >6.68% (HR2.93, 95% CI 1.30–6.58) 
and lung comet score (LCS>22; HR 2.72, 95% 
CI 1.19–6.16) independently predictive of 
mortality. Earlier study (2013) OH/ECW not 
predictive of mortality but was underpowered.
Siriopol 2017 Romania HD 285 3.4 yr Mortality N/A 89 L L M L M L OHI
In combination overhydration (>6.9%) and 
high NT-proBNP levels independently predict 
mortality (HR 1.83, CI 1.02–3.54, whereas 
in patients with normal NT-proBNP levels 
overhydration is not a predictor (HR 1.34, 95% 
CI 0.67–2.68)
Continued
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Association of BI-defined overhydration with echocardiography, cardiac biomarkers and sur-
vival in ESKD. Three cohorts explored the relationship between BI-OH and cardiac function. Two cohorts 
demonstrated that BI-OH independently predicted all-cause mortality44,55,56 and cardiovascular events44 when 
adjusted for left ventricular ejection fraction (LVEF44) and left ventricular mass (LVM44,56). In the Onofriescu et 
al. cohort, both LVEF and LVM were measured by a blinded cardiologist. Within the MVSA, relative overhydra-
tion >17.4% independently predicted mortality following adjustment for both LVEF and LVM44. In the Siropiol 
et al. cohort pre-dialysis BI-OH was used in conjunction with post-dialysis LVM and ultrasound assessment of 
pulmonary congestion (comet scores). Following adjustment for comorbidities and LVM, BI-OH and ultrasound 
comet scores were both independently predictive of mortality, with the BI-OH marker (OH/ECW > 6.68%) 
being the superior predictor56. Siropol et al. previously demonstrated that LVM was and BI-OH/LVEF were not 
independently predictive of mortality in dialysis patients, but compared with the their later work this study was 
Author(s) Year Country RRT N
Follow 
up
Prim. 
Outcome
Sec. 
Outcome
N 
(Mort)
QUIPS Criteria BIA 
Method
Outcome of Study (with appropriate MVA 
outputs, if present)SP SA PFM OM SC SAR
Tangvora-
phonkchai 2016 UK HD 362 4.1 yr Mortality N/A 110 L L L M L L OHI**
OH (%, as a continuous variable) is an 
independent predictor of mortality in MVSA 
(HR 1.15, 95% CI 1.03–1.28); co-morbidity, 
non-BIA nutritional indices, albumin and CRP 
also noted to be independent predictors of 
mortality.
Tian 2016 China PD 152 5 yrs Mortality N/A 44 L M L M M M ECWR
When adjusted for inflammation (CRP), ECWR 
(a standard deviation away from the median) is 
not predictive of mortality in PD patients (HR 
2.20, 95% CI 0.79–6.08)
Wizemann 2009 Poland HD 269 3.5 yrs Mortality N/A 86 L L L M L M OHI**
OH/ECW>15% is an independent predictor 
of mortality in HD patients (HR 2.10, 95% CI 
1.39–3.18).
Zoccali 2017 International HD 39566 1.4 yrs Mortality N/A 5866 L M L M L L OHI**
Baseline OHI/ECW>15% (men)/13% (women) 
at baseline independent predictor of mortality 
(HR 1.26, 95% CI 1.19–1.33) and in patients 
with cumulative fluid overload over a 1  yr 
period irrespective of pre-dialysis systolic BP.
Heart Failure Cohorts
Alves 2016 Brazil N/A 71 2 yrs Mortality N/A 34 L M L L H M PA**
PA < 4.8 independent predictor of mortality 
in following episodes of acute decompensated 
heart failure (HR 2.67, 95% CI 1.21–5.89). 
Ejection fraction also independent predictor of 
mortality (HR 0.94, 95% CI 0.89–1.00)
Castillo-
Martinez 2007 Mexico N/A 242 N/A
NYHA 
Class N/A Unclear L H M H H M
PA +  
BIVA****
Univariate analysis demonstrated PA predicts 
severity of symptoms (indirect measure of risk 
of hospitalisation) in both HFSD + HFPSF.
Colin-
Ramirez 2012 Mexico N/A 389 3 yrs Mortality NYHA Class 66 L L L L M M PA**
Following adjustment for age, haemoglobin and 
diabetic status, a PA < 4.2 was independently 
predictive of all cause mortality (HR 3.08, 95% 
CI 1.06–8.99).
Doesch 2010 Germany N/A 41 5 yrs Cardiac MRI data CV Mortality 8 M M L M M L PA
On univariate analysis, PA>5.5 correlated with 
CV survival, but not statistically significant 
(p = 0.13).
Sakaguchi 2015 Japan N/A 130 0.5 yrs Adverse Events CV Events
37 (2 
deaths) L L L L M L ECWR**
In acute decompensated heart failure, ECW 
ratio (measured/predicted) independent 
predictor of cardiac death/re-admission (HR 
1.48, 95% CI 1.20–1.83).
Trejo-
Velasco 2016 Spain N/A 105 0.9 yrs Mortality Readmission 19 M M L L H M BIVA**
Hyperhydration (defined by BIVA 
readings>74.3%) was an independent predictor 
of adverse outcomes (HR 2.6, 95% CI 1.1–6.4),
Table 1. Summary of studies fulfilling the search criteria. Individual patient cohorts listed according to 
author(s), year of publication (where multiple studies from the same cohort are identified, lead authors of each 
study and year of most recent study cited) and geographical location of cohort. For each cohort, the BI-OH 
markers, dialysis modalities, follow up period, number of patients within the cohort, primary/secondary 
outcomes, number of endpoints and summary of findings are provided. Summaries for each cohort are given, 
along with the appropriate BI-OH marker and its utility within the cohort to predict survival (denoted by 
the numbers of * by the BI-OH marker): * shows that the BI-OH marker is an independent predictor of the 
primary outcome (but does not report a hazard ratio/risk ratio/odds ratio and confidence interval), ** shows 
the BI-OH marker is an independent predictor of the primary outcome (and reports hazard ratio/risk ratio/
odds ratio and confidence interval), *** shows the BI-OH is an independent predictor of secondary but not 
primary outcome and **** shows that BI-OH is a univariate predictor of primary outcome. QUIPS risk of 
Bias summaries are provided for each cohort, with QUIPS domains coded as “L” for low risk of bias, “M” as 
medium risk of bias and “H” as high risk of bias. QUIPS domains include SP = Study participation, SA = Study 
attrition, PFM = Prognostic factor measurement, OM = Outcome measure, SC = Study confounding and 
SAR = Statistical analysis reporting. Randomised controlled trials (RCT) were not quality appraised using 
QUIPS as this is not a valid method of appraising methodological quality in this study design. In one study 
(highlighted ^), the follow up period was reported ambiguously and may have reflected cumulative follow up.
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Author(s) Year MVA Type Mortality Censored BIA Marker BIA Marker MVA
HR/OR for 
BIA 95% CI LL 95% CI UL
Reason for exclusion 
from MA
End-stage Kidney Failure Cohorts
Demirci 2016 Cox analysis 93 Y1,2,3 BIVA Impedance ratio HR = 1.13 1.04 1.23
Only study using 
impedance ratio for BIVA 
analysis.
Pillon/Chertow 2004 Unclear MVA 361 Y2,3,4,5 BIVA MVA using vector length (per 100ohm/m change) RR = 0.75 0.57 0.88
Only 1 study using this BIA 
method
Chen 2007 Cox analysis 58 Y1,2,3 ECW Ratio
ECW/ICW - for every 
increase by 0.1 (time 
dependent)
RR = 1.37 1.1 1.7
Only study expressing 
continuous ECW/ICW 
variable in 0.1 increments.
Fan 2015 Cox analysis 37 N ECW Ratio ECW as an absolute value (in litres) HR = 2.98 1.4 7.3
Only study expressing 
ECW as absolute volume.
Kim 2017 Cox analysis 24 Y2 ECW Ratio ECW/ICW - for every increase by 0.01 HR = 1.12 1.01 1.25
Only study expressing 
continuous ECW/ICW 
variable in 0.01 increments.
Paniagua 2010 Cox analysis 182 N ECW Ratio ECW/TBW as continuous variable in CV mortality OR = 1171.33 3.35 409899.37
Only study expressing 
ECW/TBW as continuous 
variable (expressed per 
unit ratio)
Rhee 2015 Cox analysis 15 N ECW Ratio ECW/TBW > Median HR = 1.001 1.001 1.086 Only study expressing ECW/TBW > median
Guo/Guo 2015 Cox analysis 52 Y1,2,3,4 ECW Ratio ECW/TBW > 0.4 HR = 13.12 1.35 128 Only study expressing ECW/TBW > 0.4 as cut off
Tian 2016 Cox analysis 44 N ECW Ratio ECW Ratio > 1 standard deviation from expected HR = 2.20 0.79 6.08
Only study expressing 
ECW ratio > 1 standard 
deviation from expected
O’Lone 2014 Cox analysis 95 N
ECW 
Ratio+OH 
Index
Two markers: OH/ECW 
and ECW/TBW (highest 
30% each)
HR 2.09 (1.36, 
3.20)/HR 2.05 
(1.31, 3.22)
Only study expressing both 
indices with 30% highest 
decile cut off
Caetano* 2016 Cox analysis 66 Y1,2 OH Index OH/ECW > 15% HR = 2.22 1.29 3.79 More than 1 study measuring OHI > 15%
Chazot* 2012 Cox analysis Unclear Y2,4 OH Index OHI > 15% (dHS/ECW) HR = 3.41 1.62 7.17 More than 1 study measuring OHI > 15%
Dekker* 2017 Cox analysis Unclear Y1,2.3,4 OH Index OHI/ECW > 15% (overhydration 2.5–5L) HR = 2.62 2.1 3.3
More than 1 study 
measuring OHI > 15%
Hoppe 2015 MLR Unclear N OH Index Continuous variable OR = 1.12 0.92 1.37
Only study expressing OHI 
as continuous variable 
in MLR
Huan-Sheng 2016 Cox analysis 13 N OH Index
Absolute OH; BIA-defined 
protocol linked with 
episodes of absolute fluid 
overload to determine 
management
RCT - testing an 
intervention vs. control, 
non comparable design.
Jotterand-
Drepper* 2016 Cox analysis 19 Y
1,2,3 OH Index OHI/ECW > 15% HR = 7.82 1.1 29.07 More than 1 study measuring OHI > 15%
Kim* 2015 Cox analysis 50 Y2 OH Index OH/ECW > 15% HR = 2.58 1.16 5.75 More than 1 study measuring OHI > 15%
Mathew 2015 MLR 41 Y2,3 OH Index Absolute OH > Median (3.1L) OR = 2.96 1.04 8.46
Only study expressing 
OHI > median
Onofriescu 2014 Cox analysis 9 Y2,3 OH Index
OH/ECW > 15% used 
to define BIA-defined 
overhydration in RCT of 
BIA-driven vs standard 
care.
RCT - testing an 
intervention vs. control, 
non comparable design.
Onofriescu* 2015 Cox analysis 66 Y1,2,3,4 OH Index RFO (OH/ECW) > 15% and  > 17.4% 15%: HR 1.87 1.12 3.13
More than 1 study 
measuring OHI > 15%
Siriopol/
Siriopol 2015 Cox analysis 31 Y
1,2,4 OH Index OH/ECW > 6.68% HR = 2.93 1.3 6.58 Only study expressing OHI > 6.68%
Siriopol 2017 Cox analysis 89 Y1,2,4 OH Index OH/ECW > 6.9% HR = 1.34 0.67 2.68 Only study expressing OHI > 6.9%
Tangvorap-
honkchai 2016 Cox analysis 110 N OH Index
OH as a continuous 
variable HR = 1.15 1.03 1.28
Only study expressing OHI 
as a continuous variable in 
Cox regression.
Wizemann* 2009 Cox analysis 86 Y2,4 OH Index OH/ECW > 15% HR = 2.10 1.39 3.18 More than 1 study measuring OHI > 15%
Zoccali* 2017 Cox analysis 5866 N OH Index OH/ECW > 15% in males and > 13% in females HR = 1.26 1.19 1.33
More than 1 study 
measuring OHI > 15%
Bebera-shvili** 2014 Cox analysis 38 N PA 1 degree increase PA (time varying risk) HR = 0.61 0.53 0.71
More than 1 study 
expressing PA as 
continuous variable
Bebera-shvili** 2014 Cox analysis 64 Y2,3 PA PA - continuous variable in MVA HR = 0.72 0.54 0.96
More than 1 study 
expressing PA as 
continuous variable
Continued
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underpowered55. Four cohorts adjusted for BNP in MVSA; 1 study demonstrated both BNP and BI-OH as a inde-
pendent predictors of mortality45, 2 studies demonstrated that BI-OH was predictive of mortality whereas BNP 
was not35,58 and 1 study demonstrated an additive effect57.
Association of BI-defined overhydration with morbidity and mortality in Heart Failure. Five 
heart failure cohorts demonstrated an association between BI-OH and adverse patient outcomes (13,18,21,51,60, Table 
1). One cohort undertook univariate analyses and demonstrated BI-OH values predicted the severity of HF symp-
toms (NHYA classification) in heart failure18. Four cohorts included MVSA, adjusting for covariates such as age 
(100% of MVSA), diabetic status (25%), renal dysfunction (50%), LVEF (50%), BNP (25%) and haemoglobin/
haematinics (50%). In all four cohorts with a MVSA BI-OH was independently predictive of all cause mortal-
ity13,21,60 and adverse events51.
Quantitative pooling (sub-group meta-analysis) of BI-OH as a predictor of mortality in ESKF 
cohorts. Within 38 ESKF cohorts containing a MVSA, 32 reported adjusted hazard or odds ratio data 
for mortality for BI-OH measures along with 95% confidence intervals. Of these, 12 cohorts were eligible for 
meta-analysis (1,2,15–17,23,35,37,38,44,54,61, Table 2); 8 cohorts using an overhydration index cut off of OH/ECW > 15% 
and 4 cohorts using PA as a continuous variable. A 1-degree decrease in PA (HR 1.74, 95% CI 1.37–2.21, 
P < 0.001) and OH > 15% (HR 2.28, 95% CI 1.56–3,34, P < 0.001) were both predictive of mortality (Fig. 3), 
supporting the findings from the narrative synthesis of the evidence (Tables 1 and 2).
Methodological quality of studies. Methodological quality varied widely between studies. Where more 
than one study was present within a cohort, the study where data was extracted for the review was appraised 
for methodological quality. Within all studies (Fig. 4), the majority of studies when assessed for ROB in 
study participation (62%2,12,13,15,16,18,19,21,23–25,27,29,31,32,35,36,38,42,44,46,51–59,61), study attrition (51%1,2,15–17,19–24,30–
32,35,36,39,40,42,44,45,47,51,57,58), prognostic factor measurement (56%1,2,13,15–17,20,21,24,26,28,31,32,37–41,47,49–51,58–61) and out-
come measurement (60%1,12,13,15,16,19,21,22,24,27,30–32,35–42,44,45,49,51,55–57,60) were deemed low ROB. In contrast, when 
assessing ROB in study confounding and statistical analyses, only 27%2,12,17,19,22,25,38,44,46,52,53,58,61 and 36%15,22,26,27,30–
32,40,41,44,45,49,51–53,57,58,61 of studies had low ROB respectively. At the individual study level (Table 1) no study was 
rated as low risk or high risk of bias (ROB) in all six domains.
Discussion
This systematic review provides strong narrative evidence, supported by quantitative evidence from a subgroup 
meta-analysis, that bio-impedance defined overhydration (BI-OH) is an independent predictor of mortality in 
ESKF patients. It is the first systematic review exploring this question and the first to demonstrate that different 
BI-OH metrics, such as phase angle or overhydration index (OHI), act as similar predictors of outcome, with 
overhydration defined by PA or OHI in the subgroup meta-analysis being associated with approximately double 
Author(s) Year MVA Type Mortality Censored BIA Marker BIA Marker MVA
HR/OR for 
BIA 95% CI LL 95% CI UL
Reason for exclusion 
from MA
Fiedler 2009 Cox analysis 36 Y2 PA PA < 4 HR = 2.34 1.O6 5.14 Only study expressing PA < 4
Koh** 2011 Cox analysis 35 N PA PA - continuous variable in MVA HR = 0.39 0.27 0.57
More than 1 study 
expressing PA as 
continuous variable
Segall/Segall 2014 Cox analysis 11 N PA PA < 5.58 HR = 2.15 1.16 3.99 Only study expressing PA < 5.58
Shin** 2017 Cox analysis 15 N PA PA - continuous variable in MVA HR = 0.56 0.33 0.97
More than 1 study 
expressing PA as 
continuous variable
de Araujo 2013 Cox analysis 13 Y1,2,4,6 PA+ECW Ratio
Stratified for diabetic status 
- PA predictive in nonDM/
not predictive in DM
Stratified for diabetic status 
with two separate analyses
Heart Failure Cohorts
Trejo-Velasco 2016 Cox analysis 19 N BIVA BIVA Hyperhydration (defined as > 74.3%) HR = 2.60 1.10 6.40
Only study expressing 
BIVA
Sakaguchi 2015 Cox analysis 37 N ECW Ratio ECW Ratio (measured/predicted) HR = 1.48 1.20 1.83
Only study expressing 
ECW ratio (measured/
predicted)
Alves 2016 Cox analysis 34 N PA PA < 4.8 HR = 2.67 1.21 5.89 Only study expressing PA < 4.8
Colin-Ramirez 2012 Cox analysis 66 N PA PA < 4.2 HR = 3.08 1.06 8.99 Only study expressing PA < 4.2
Table 2. Summary of cohorts reporting multivariate analyses with a stated hazard ratio, (HR) risk ratio (RR) 
or odds ratio (OR), 95% confidence intervals, (CI) lower limit (LL) and upper limit (UL). Authors highlighted 
with * or ** had their studies included within the final subgroup meta-analysis. Censoring, where used within 
MVSA, are stated, with reasons including: Transfer to another RRT modality (1), transplantation (2), loss to 
follow up (3), transfer to another dialysis facility (4), withdrawal from RRT (5) or, in the case of one paper death 
due to non-cardiovascular cause (6).
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the risk of mortality compared with normohydrated patients. Furthermore, this is the first review to demonstrate 
that whole body BI-OH is an independent predictor of mortality in HF, suggesting a role for overhydration as a 
useful prognostic marker across different chronic disease groups.
BI-OH remained independently predictive of mortality or hospitalisation in all ESKF cohorts following 
adjustment for body mass index (BMI;1,17,23,24,40,43,52,53,61), subjective global assessment (SGA19,30,39,52,53), normal-
ised protein nitrogen appearance (nPNA39,52,53) and malnutrition inflammation score (MIS16,30). This suggests 
that the additional predictive value of BI-OH is not confined to its ability to identify lean body mass cachexia but 
that it is also identifying absolute or relative expansion of the extracellular fluid volume as an independent risk. 
The association of ECFv expansion with malnutrition is not new, having been observed previously, using gold 
standard techniques of volume measurement in populations with cachexia due to poverty-related starvation62. 
However there are a number of additional explanations for this in the ESKD population, some of which were 
adjusted for in studies included in this review. Chronic inflammation (c-reactive protein or interleukin-6) was 
adjusted for in multiple cohorts (Table 2) and was itself an independent predictor of mortality in 43% of cohorts, 
without nullifying BI-OH as a predictor of mortality. This association63,64 is likely explained by the observation 
that inflammation drives lean body mass cachexia, with such changes being potentially driven by translocation of 
bacterial endotoxins across an oedematous bowel wall in overhydrated ESKF patients65,66. Chronic inflammation 
also contributes towards hypoalbuminaemia, which in our cohorts was demonstrated to a predictor of mortality 
in ESKF in half of all cohorts adjusting for it in MVSA; a finding consistent with previous studies that suggest 
hypoalbuminaemia may contribute towards intradialytic hypotension in haemodialysis and extravascular tissue 
oedema in peritoneal dialysis64,67,68. And yet, as demonstrated with chronic inflammation, hypoalbuminaemia did 
not nullify the ability of BI-OH to predict mortality in most cohorts, again suggesting the influence of overhydra-
tion on mortality in ESKF is synergistic. Cachexia, inflammation and hypoalbuminaemia is a common triad in 
many chronic diseases69, including in chronic kidney disease69,70, supporting the argument that overhydration in 
chronic diseases, as opposed to a catabolic metabolism, is contributing to poor outcomes.
Echocardiographic abnormalities are common in ESKF; one previous study estimating the prevalence of 
left ventricular hypertrophy and systolic dysfunction in dialysis patients to be 74% and 15% respectively71. Our 
review demonstrates BI-OH remains an independent predictor of mortality even in the presence of abnormal left 
ventricular ejection fraction (LVEF44) and mass index (LVMI56). Although cautious interpretation is warranted 
given the small number of cohorts including echocardiogram data, our findings add weight to the developing 
narrative that cardiac structural disease, particularly left ventricular systolic dysfunction (LVSD), may not be the 
sine qua non underlying excess mortality in overhydrated ESKF patients. The link between BI-OH and adverse 
cardiovascular events has been previously noted; BI-OH previously being correlated with endothelial dysfunc-
tion72, arterial stiffness43 and the development of left ventricular hypertrophy (LVH73,74). In studies exploring 
sudden cardiac death in ESKF, LVH was predictive of mortality even when adjusting for blood pressure, whereas 
LVSD played no such role in predicting mortality. What cannot be answered by current evidence is whether 
LVH precipitates sudden cardiac death or whether LVH merely acts as a surrogate for overhydration, since the 
Onofriescu et al. study demonstrated improvements in LVH correlated with improvements in BI-OH measure-
ments43. Furthermore, a recent systematic review and meta-analysis by Badve et al. suggests that in CKD, inter-
ventions to reduce LVH through altering volume status are not consistently effective, and even where they do 
reduce LVH (for example through improving haemoglobin or renin-angiotensin blockade), no survival benefit 
has been seen75. The role of BNP as a predictor of overhydration and mortality was explored in four cohorts and 
data from one suggested a role for both BNP and BI-OH as independent predictors of mortality, albeit echocar-
diography was not included in this analysis. One hypothesis is that mortality in overhydrated ESKF patients may 
be driven by the dialysis prescription76, with greater ultrafiltration rates during dialysis having been previously 
demonstrated to induce HD-induced cardiac injury in the form of regional wall motion abnormalities subclinical 
myocardial ischaemia77,78. However, given that two cohorts demonstrated a role for BI-OH and not BNP as inde-
pendent predictors of mortality, there is still much to be learned about the interaction of cardiac biomarkers and 
overhydration in predicting outcomes in dialysis patients.
Two recently published large international studies are included in our review23,61. Dekker et al. demonstrated 
in a European multinational cohort using data from 5450 selected HD patients that baseline pre-dialysis BI-OH 
(where the definition of severe fluid overload was >2.5 L absolute overhydration) predicted increased mortality 
when adjusted for multiple demographic and co-morbidity covariates. Furthermore this study demonstrated an 
additive risk of mortality in overhydrated patients with chronic inflammation23. The second study, by Zoccali 
et al., demonstrated in an multinational cohort using data from 39,566 ESKF patients that when adjusted for 
multiple demographic and co-morbidity covariates that overhydration at baseline, defined as an OHI > 15% for 
men and >13% for women, is an independent predictor for mortality61. They also explored the well established 
J-shaped relationship between pre-dialysis blood pressure and mortality, finding that higher mortality in over-
hydrated compared with normohydrated patients is observed across all blood pressure strata, and demonstrated 
that overhydration remained an independent predictor of mortality with cumulative BI-OH measurements over 
a one year period61. The inclusion of these studies adds significant value to our narrative and pooled summaries, 
establishing that in approximately 50,000 dialysis patients baseline OHI > 15% is predictive of mortality despite 
adjustment for multiple comorbidities and inflammation.
Our review has several strengths, including the use of systematic methods to identify studies, independent 
reviewers throughout the study selection, review and quality appraisal process and the inclusion of heart fail-
ure studies as a comparator group, to explore the role of BI-OH in different chronic disease states. It is the first 
attempt to our knowledge, to summarise and compare the utility of different BI-OH measures in predicting 
mortality. The review does however have several limitations. Methodological heterogeneity within the studies 
was considerable, with common sources of bias including unclear study design14,20,47,50, inadequate reporting 
of cohort demographics1,2,20,26,28,31,32,40,41,43–45,47,50, inadequate description or insufficient numbers of endpoi
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nts2,17,18,20,22,25,28,29,31,32,37,46,47,49–51,55,56, lack of clarity regarding the protocol for the measurement of BI-OH16,17,19,31–
33,45,46,55,56, exclusion of clinically relevant covariates from MVA26,30–33,37,40 and a lack of clarity regarding the sta-
tistical methods used during survival analysis2,14,16,18–21,26,29,39,46,47. In some studies there was a failure to adjust 
for HIV status in cohorts where prevalence of HIV is high or where the large proportions of the population is 
African-Americans;20,22,29,38,47,49 importantly BI-defined cachexia is associated with HIV infection and therefore 
potentially confounds the association of BI-OH and mortality. Finally considerable heterogeneity within BI-OH 
method reporting, and particularly the use of different BI devices which use different “normal populations” to 
define their BI-OH cut offs, limited the scope for performing a comprehensive pooled survival analysis. This 
particularly explains why all cohorts expressing BI-OH using the ECWR method could not be pooled, as they all 
depend on the algorithms used for total body water estimation, which differs between devices3 and is potentially 
confounded by ethnicity. Given the anticipated heterogeneity within our pooled analysis we followed the recom-
mendation of Higgins et al. when planning our meta-analysis79, including the use of a random effects method, 
assessing for a consistent pattern in the directionality of the results in included studies and the use of studies 
which adjust for the effects of covariates on the outcome variable.
This review clearly establishes BI-OH as a predictor of survival in ESKF patients, independent of the effect of 
malnutrition, inflammation, multimorbidity and within a few cohorts, cardiac structural disease. Similar conclu-
sions are noted in HF patients, suggesting a role for overhydration in predicting poor outcomes in other chronic 
diseases - a hypothesis which should be tested in other disease groups. The evidence presented necessitates 
Figure 3. Summary of subgroup meta-analysis. The pooled summary of the effect of OH > 15% and a 1-degree 
decrease in PA on mortality in the dialysis population. 95% CI = 95% confidence interval, IV = inverse variance 
method.
Figure 4. Summary of the QUIPS analysis from all cohorts included within the systematic review. SP = study 
participation, SA = study attrition, PFM = prognostic factor measurement, OM = outcome measure, SC = study 
confounding and STR = statistical analysis reporting.
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further investigation into the pathogenic role of overhydration, for example through real-time cardiac imaging 
and ultrafiltration rate during dialysis or the prognostic value of BI-OH in preventing volume related deaths 
contributing to the increased mortality observed during the 3-day break. Likewise, it does not establish the value 
of BI-OH as a tool for goal directed fluid management. Although recent trials suggest that use of BI can improve 
fluid status and blood pressure, as summarised by Covic et al. in a systematic review and in the recent UK NICE 
guidelines80–82, with further studies are on-going83, there is no clear benefit on all-cause mortality.
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